Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1–5: Development and Immunohistochemical Application in Neuroendocrine Tumors
Authors:
- Herbert A. SchmidHSHerbert A. Schmid
- Chiara LambertiniCLChiara Lambertini
- Harmke H. van VugtHVHarmke H. van Vugt
- Patrizia Barzaghi-RinaudoPBPatrizia Barzaghi-Rinaudo
- Judith SchäferJSJudith Schäfer
- Rainer HillenbrandRHRainer Hillenbrand
- Andreas W. SailerASAndreas W. Sailer
- Martina KaufmannMKMartina Kaufmann
- Paolo NuciforoPaolo Nuciforo
- 13 December 2011
- journal article
- Published by S. Karger AG in Neuroendocrinology
- Vol. 95 (3) , 232-247
Abstract
Background: Activation of somatostatin receptors (sstr1–5) by somatostatin and its analogues exerts an inhibitory effect on hormone secretion and provides the basis for the treatment of a range of endocrine diseases such as acromegaly, Cushing’s disease and neuroendocrine tumors (NET). The lack of well-characterized commercially available sstr subtype-specific antibodies prevents routine identification of the sstr expression profile in patients. Methods: We generated and characterized new mouse monoclonal antibodies (mAbs) targeting the five human sstr subtypes using ELISA and immunohistochemistry, and tested their suitability in formalin-fixed and paraffin-embedded (FFPE) human tissues and archival samples of normal pancreatic tissue and NET. Results: All mAbs were highly specific with no cross-reactivity. The sstr1–5 immunoreactivity in gastrointestinal NET (n = 67) was correlated with clinicopathologic data. With the exception of sstr3, NET were highly positive for all receptor subtypes (42, 63, 6, 32 and 65% of tumors were positive for sstr1, sstr2a, sstr3, sstr4 and sstr5, respectively). sstr1, sstr2a and sstr5 were present at the plasma membrane and in the cytoplasm of tumor cells, whereas sstr3 and sstr4 were almost exclusively cytoplasmic. Immunoreactivity of sstr1, sstr2a and sstr4 tended to decrease as tumor aggressiveness increased. sstr5 showed an opposite pattern, with higher staining in well-differentiated carcinomas compared with well-differentiated tumors. sstr5 immunoreactivity was correlated with the presence of metastases and angioinvasion, suggesting a possible association with more aggressive behavior. Conclusion: Determination of the sstr1–5 by immunohistochemistry using subtype-specific mAbs is feasible in FFPE tissue and may provide a tool for routine clinical practice.Keywords
This publication has 62 references indexed in Scilit:
- Internalized Somatostatin Receptor Subtype 2 in Neuroendocrine Tumors of Octreotide-Treated PatientsThe Journal of Clinical Endocrinology & Metabolism, 2010
- Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigationThyroid Research, 2009
- Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumoursBest Practice & Research Clinical Endocrinology & Metabolism, 2005
- Future Aspects of Somatostatin- Receptor-Mediated TherapyNeuroendocrinology, 2004
- Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) Part II—Specific NE Tumour TypesActa Oncologica, 2004
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinomaThe Journal of Clinical Endocrinology & Metabolism, 1995
- Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implicationsThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Basic local alignment search toolJournal of Molecular Biology, 1990
- SMS 201–995: A very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sciences, 1982